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MaBACKGROUND Although N-terminal pro–B-type natriuretic peptide (NT-proBNP) has a strong relationship with
incident cardiovascular disease (CVD), few studies have examined whether NT-proBNP adds to risk prediction algorithms,
particularly in women.
OBJECTIVES This study sought to evaluate the relationship between NT-proBNP and incident CVD in women.
METHODS Using a prospective case-cohort within the WHI (Women’s Health Initiative) observational study, we selected
1,821 incident cases of CVD (746 myocardial infarctions, 754 ischemic strokes, 160 hemorrhagic strokes, and 161 other
cardiovascular [CV] deaths) and a randomly selected reference cohort of 1,992 women without CVD at baseline.
RESULTS Median levels of NT-proBNP were higher at study entry among incident cases (120.3 ng/l [interquartile range
(IQR): 68.1 to 219.5 ng/l]) than among control subjects (100.4 ng/l [IQR: 59.7 to 172.6 ng/l]; p < 0.0001). Women in the
highest quartile of NT-proBNP ($140.8 ng/l) were at 53% increased risk of CVD versus those in the lowest quartile after
adjusting for traditional risk factors (1.53 [95% conﬁdence interval (CI): 1.21 to 1.94]; p for trend <0.0001). Similar
associations were observed after adjustment for Reynolds Risk Score covariables (1.53 [95% CI: 1.20 to 1.95]; p for
trend <0.0001); the association remained in separate analyses of CV death (2.66 [95% CI: 1.48 to 4.81]; p for
trend <0.0001), myocardial infarction (1.39 [95% CI: 1.02 to 1.88]; p for trend ¼ 0.008), and stroke (1.60 [95% CI: 1.22
to 2.11]; p for trend <0.0001). When added to traditional risk covariables, NT-proBNP improved the c-statistic (0.765 to
0.774; p ¼ 0.0003), categorical net reclassiﬁcation (0.08; p < 0.0001), and integrated discrimination (0.0105;
p < 0.0001). Similar results were observed when NT-proBNP was added to the Reynolds Risk Score.
CONCLUSIONS In this multiethnic cohort of women with numerous CV events, NT-proBNP modestly improved
measures of CVD risk prediction. (J Am Coll Cardiol 2014;64:1789–97) © 2014 by the American College of Cardiology
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ABBR EV I A T I ON S
AND ACRONYMS
CVD = cardiovascular disease
HDL-C = high-density
lipoprotein cholesterol
hsCRP = high-sensitivity
C-reactive protein
IDI = integrated
discrimination improvement
NP = natriuretic peptide
NRI = net reclassiﬁcation
improvement
NT-proBNP = N-terminal
pro-B-type natriuretic peptide
RRS = Reynolds Risk Score
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1790A ssays for B-type natriuretic peptides(NPs) have gained widespread accep-tance as tools for diagnosis and risk
stratiﬁcation in patients experiencing short-
ness of breath and chest pain (1–3). NPs also
have demonstrated consistent association
with adverse cardiovascular (CV) outcome
in stable patients with and without estab-
lished cardiovascular disease (CVD) (4). How-
ever, few studies conducted in general
populations have analyzed the association
of NPs with CVD, speciﬁcally in women, and
only a handful have comprehensively exam-
ined whether NPs improve clinical risk pre-
diction in the general populations (5–8).SEE PAGE 1798Women have higher levels of NPs than men
(5,9–13), and yet they have a lower absolute risk for
CVD than men of similar age and risk factor burden
(14). Obesity is also well known to affect NP levels in
both whites and blacks (15,16), and differential pat-
terns of adipose tissue in men and women may alter
the relationship between NPs and CVD, as has been
observed for other CVD risk markers (17). Reportedly,
NP concentrations are lower in blacks than whites
(18,19). In fact, although the relationship between
NPs and CV risk appears consistent across several
studies including general populations, many studies
include only men (6,20), report the number of CVD
events in women but do not report the association
between NPs and CVD in women and men separately
(7,11), or have too few events in women to analyze
(13). Data on the relationship between NPs and CVD in
women of nonwhite race/ancestry are even scarcer.
To better understand the relationship between NPs
and CV risk in a broad population of women, we con-
structed a prospective, case-cohort study within the
multiethnic Women’s Health Initiative (WHI), and
measured N-terminal pro–B-type natriuretic peptide
(NT-proBNP) concentrations at baseline in 1,821
women who subsequently had a major CV event
(myocardial infarction [MI], stroke, or CV death) and a
reference cohort of 1,992 women. We then tested
whether the addition of NT-proBNP concentrations to
traditional CVD risk markers, such as those included in
the Framingham CVD score (21) or Reynolds Risk Score
(RRS) (22), improved our ability to predict CV risk.
METHODS
STUDY POPULATION. This study includes partici-
pants in the WHI observational study (WHI-OS)
and the WHI extension study. The WHI-OS is amultiethnic cohort of 93,676 post-menopausal
women, aged 50 to 79 years at recruitment, who
were enrolled between 1994 and 1998 at 40 sites
across the United States. The racial/ethnic composi-
tion of the WHI-OS is representative of U.S. women in
the included age groups. Of the 93,676 women in the
WHI-OS, 71,872 had no prior history of MI, stroke,
peripheral artery disease, venous thromboembolism,
or cancer. Of those, 60,890 had baseline blood sam-
ples available for analysis.
Baseline information on medical history, health
behaviors, and blood pressure (BP) measurements
were collected by the WHI-OS clinical centers. Infor-
mation on diabetes, smoking, family history of CVD,
and medication use were self-reported.
OUTCOMES. The primary endpoint for this study was
a composite of major CVD, deﬁned as the occurrence
of nonfatal MI, nonfatal stroke, or CV death. Chronic
heart failure (HF) was not included as part of the
primary CV endpoint. CVD outcomes were self-
reported and physician-veriﬁed via review of car-
diac biomarkers, electrocardiograms, and medical
records as previously described (23). Coronary heart
disease was deﬁned as nonfatal MI and coronary
death, and stroke was deﬁned as a fatal or nonfatal
persistent neurologic deﬁcit of at least 24-h duration
that was sudden in onset and compatible to
obstruction or rupture of a cerebral artery. Strokes
were classiﬁed as ischemic or hemorrhagic on the
basis of brain imaging reports. Deaths were classiﬁed
on the basis of death certiﬁcates, autopsy reports,
and medical records.
SAMPLE SELECTION. A prospective case-cohort de-
sign was employed. A total of 2,000 women with
incident CVD were selected for inclusion. We ﬁrst
included all incident cases among black (n ¼ 200),
Hispanic (n ¼ 53), and Asian/Paciﬁc Islander (n ¼ 55)
women, as well as 55 cases from women of unknown
or other race/ethnicity groups. The remaining 1,637
cases were randomly selected from among 2,370
cases of incident CVD in white women. A reference
cohort of approximately 2,000 women was selected
using the same eligibility criteria and frequency
matched by race/ethnicity and age (in 5-year groups).
Women who developed CVD during follow-up were
eligible to be selected as reference cohort members,
but women who had prevalent CVD at enrollment,
including transient ischemic attack, HF, or CV sur-
gery, or who had no valid measurement of NT-proBNP
(n ¼ 2) were excluded from both the case and refer-
ence groups. After these exclusions, the ﬁnal sample
included 1,821 cases of CVD and a reference cohort of
1,992 women, of whom 132 were also cases.
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1791LABORATORY ANALYSIS. Plasma samples were col-
lected and stored centrally at 70C and assayed for
NT-proBNP, total cholesterol, high-density lipoprotein
cholesterol (HDL-C), high-sensitivity C-reactive pro-
tein (hsCRP), and glycated hemoglobin A1c (the
latter only among patients with diabetes) in a core
laboratory certiﬁed by the National Heart, Lung, and
Blood Institute/Centers for Disease Control and Pre-
vention Lipid Standardization Program. NT-proBNP
was measured using an electrochemiluminescent
immunoassay from Roche Diagnostics (Indianapolis,
Indiana).
STATISTICAL ANALYSIS. We estimated means and
proportions in both the cases and the reference co-
horts in a crude analysis. Overall population charac-
teristics were estimated using inverse probability
weights in PROC SURVEYMEANS and SURVEYFREQ
in SAS version 9.2 (SAS Institute, Cary, North Car-
olina) to reﬂect the sampling in the total WHI cohort.
Because the numbers in the full sample were
known, our stratiﬁed sampling enabled us to mimic or
recapture the characteristics of the full WHI cohort
using reweighting by sampling frequency. The
numbers of women among the cases and reference
cohort who were above the age-speciﬁc NT-proBNP
thresholds for acute HF in patients with dyspnea
(>900 ng/l for ages 50 to 75 years and >1,800 ng/l for
ages >75 years) were compared using the chi-square
test (3). Cox proportional hazards models were used
to test the association of NT-proBNP with incident
CVD in all women, regardless of race/ethnicity. Pre-
viously described methods for proportional hazards
regression in case-cohort samples, with appropriate
weighting, were used (24–26). Using quartiles derived
from all women selected for the reference cohort, the
association of NT-proBNP with the composite CV
outcome was tested in a series of adjusted models.
The risk per 1-SD unit in Ln-transformed NT-proBNP
(Ln–NT-proBNP) also was calculated. The ﬁrst model,
called the “multivariable model,” was adjusted for
age and race/ethnicity as well as underlying condi-
tions and medication use (prior diabetes, angina,
statin use, and current and past hormone therapy).
We then constructed a “multivariable plus traditional
risk factor” model that adjusted for covariables from
the multivariable model above, plus the traditional
risk markers that are included in the Adult Treatment
Panel III risk model (27), the Framingham CVD risk
score (21), and the American College of Cardiology/
American Heart Association 2013 pooled cohort
atherosclerotic CVD risk model (28): current smoking;
the natural logs of systolic BP, total cholesterol, and
HDL-C; and treatment for high BP. We also con-
structed a “Reynolds Risk Score” model that adjustedfor covariables included in the multivariable model
plus the variables in the RRS: current smoking; the
natural logs of systolic BP, total cholesterol, HDL-C,
and hsCRP; family history of premature MI; and gly-
cated hemoglobin A1c among women with diabetes
(22). In sensitivity analyses, body mass index (BMI)
was included with the other covariables in the
multivariable plus traditional risk factor and RRS
models. We repeated the adjusted proportional haz-
ards analysis for CV death, incident fatal/nonfatal
MI, incident fatal/nonfatal stroke, and in analyses
stratiﬁed by baseline characteristics. The Bonferroni-
corrected p value for evidence of statistically sig-
niﬁcant interaction in the stratiﬁed analysis was
p < 0.00278 (p ¼ 0.05/18 tests).
To directly compare the performance of the
multivariable plus traditional risk factor model and
RRS model with and without NT-proBNP, we calcu-
lated the c-statistics for each model and the inte-
grated discrimination improvement (IDI) (29). To
determine whether NT-proBNP improved our ability
to classify women into 10-year CVD risk categories
of <5%, 5% to <10%, 10% to <20%, and $20%, we
calculated the net reclassiﬁcation improvement (NRI)
(28). Survival methods were used throughout (30,31),
and measures were reweighted to reﬂect the distri-
bution in the overall cohort. Statistical tests of
discrimination measures were performed using
bootstrap samples. We also performed sensitivity
analyses by including diabetes, angina, statin use,
and current and past hormone therapy with the RRS
covariables.
RESULTS
A total of 1,821 women who developed CVD during
follow-up met the criteria for inclusion as cases,
whereas 1,992 women met criteria for inclusion in the
reference cohort. In total, there were 746 fatal/
nonfatal MIs, 754 fatal/nonfatal ischemic strokes, 160
fatal/nonfatal hemorrhagic strokes, and 161 other CV
deaths. The median follow-up time was 9.9 years
(interquartile range: 8.0 to 11.6 years).
The study population’s baseline characteristics
presented both as crude analyses and in analyses
reweighted to reﬂect sampling from the WHI popu-
lation are displayed in Table 1. As anticipated, women
who developed CVD during follow-up had higher
BMIs, systolic BP, and hsCRP, and lower HDL-C
levels. These women were also more likely to be
current smokers, use loop diuretics, and have dia-
betes, a history of angina, or family history of
premature MI. In both crude and reweighted ana-
lyses, NT-proBNP levels were signiﬁcantly higher
TABLE 1 Comparisons of Baseline Characteristics of CVD Cases and Random Cohort, in the Sample and Reweighted to the Total WHI Cohort
Crude Reweighted to Population
Cohort (n ¼ 1,992) Cases (n ¼ 1,821) p Value Cohort Cases p Value
Age, yrs 67.7  0.2 67.8  0.2 0.11 62.7  0.04 67.9  0.03 <0.001
Race/ethnicity
Black 204 (10.2) 186 (10.2) 0.96 4,207 (7.2) 186 (7.6) 0.61
White 1,622 (81.4) 1,489 (81.8) 0.65 49,410 (84.7) 2,106 (86.4) 0.12
Hispanic 57 (2.9) 50 (2.8) 0.99 2,044 (3.5) 50 (2.1) 0.02
Asian 54 (2.7) 50 (2.8) 0.77 1,749 (3.0) 50 (2.1) 0.05
Other race/unknown race 55 (2.8) 46 (2.5) 0.48 914 (1.6) 46 (1.9) 0.51
Height, cm 160.9  0.2 160.8  0.2 0.78 161.5  0.3 160.9  0.1 0.095
Weight, kg 70.0  0.3 72.2  0.4 <0.0001 72.0  0.6 72.1  0.4 0.85
BMI, kg/m2 26.9  0.1 27.9  0.1 <0.0001 27.3  0.2 27.8  0.1 0.057
Current smoking 96 (4.8) 161 (8.8) <0.0001 3,310 (5.7) 207 (8.5) 0.009
Hormone therapy
Current 830 (41.7) 719 (39.6) 0.12 27,986 (48.0) 977 (40.1) <0.0001
Past 286 (14.4) 276 (15.2) 0.53 7,051 (12.1) 375 (15.4) 0.013
Blood pressure, mm Hg
Systolic 129.7  0.4 135.5  0.4 <0.0001 126.3  0.5 135.3  0.4 <0.0001
Diastolic 74.3  0.2 75.8  0.2 <0.0001 74.8  0.3 75.7  0.2 0.012
Antihypertensive medication use 529 (26.6) 658 (37.7) <0.0001 13,091 (22.5) 909 (37.3) <0.0001
Total cholesterol, mg/dl 230.9  1.0 228.0  1.0 0.047 231.0  1.5 228.4  1.0 0.17
HDL, mg/dl 56.8  0.4 51.1  0.4 <0.0001 56.6  0.5 51.1  0.4 <0.0001
Cholesterol-lowering medication 178 (8.9) 176 (9.7) 0.55 4,359 (7.5) 236 (9.7) 0.037
Statin use 161 (8.0) 134 (7.4) 0.30 3,921 (6.7) 180 (7.4) 0.54
Loop diuretic use 48 (2.4) 71 (3.9) 0.002 1,188 (2.0) 92 (3.8) 0.006
hsCRP, mg/l* 2.3 (1.0–5.0) 3.0 (1.4–4.9) <0.0001 2.4 (1.0–5.2) 3.0 (1.3–6.0) <0.0001
Diabetes 93 (4.7) 189 (10.4) <0.0001 2,151 (3.7) 238 (9.8) <0.0001
HbA1c (if diabetic) 7.4 (0.2) 7.9 (0.1) 0.013 7.5 (0.2) 7.9 (0.1) 0.0099
Angina 55 (2.8) 83 (4.6) 0.004 1,314 (2.3) 112 (4.6) 0.0007
Family history of early MI 352 (17.7) 483 (22.1) 0.0002 11,413 (19.6) 552 (22.7) 0.042
NT-proBNP, pg/ml 100.4 (59.7–172.6) 120.3 (68.1–219.5) <0.0001 82.7 (50.9–140.8) 122.4 (69.4–219.7) <0.0001
Abnormal NT-proBNP† 17 (0.9) 49 (2.7) <0.0001 312 (0.5) 65 (2.7) <0.0001
Values are mean  SE, n (%), or median (interquartile range). *Test is based on natural logs. †NT-proBNP >900 ng/l for ages 50 to 75 years and >1,800 ng/l for ages
>75 years.
BMI ¼ body mass index; CVD ¼ cardiovascular disease; HbA1c ¼ hemoglobin A1c; HDL ¼ high-density lipoprotein; hsCRP ¼ high-sensitivity C-reactive protein;
MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; WHI ¼ Women’s Health Initiative.
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1792among women who developed incident CVD (each
p < 0.0001). In total, there were 8 cases with NT-
proBNP concentrations above the age-speciﬁc cut
points used to diagnose HF in patients with dyspnea
(3) compared with only 1 in the reference cohort
(p ¼ 0.004) (Table 1).
The relationship between NT-proBNP levels and
baseline characteristics of the reference cohort are
displayed in Online Table 1. Increasing levels of NT-
proBNP were associated with increasing age, systolic
BP, and HDL-C; increased antihypertensive and hor-
mone therapy use; and lower levels of BMI and
hsCRP. No signiﬁcant relationship was observed be-
tween NT-proBNP levels and total cholesterol, cur-
rent smoking, diabetes, angina, loop diuretic use, or
family history of premature MI. We observed a higher
proportion of white women in the higher quartiles ofNT-proBNP and the opposite pattern for black women
(each p < 0.0001).
Increasing levels of NT-proBNP showed a positive
relationship with incident CVD (Table 2) that re-
mained signiﬁcant after adjusting for covariables
included in the traditional risk factor or RRS models.
For example, relative to the women in the lowest
quartile of NT-proBNP, women in the highest quartile
were at 53% increased risk of CVD after adjusting for
either the traditional risk factor covariables (hazard
ratio [HR]: 1.53; 95% conﬁdence interval [CI]: 1.21
to 1.94; p for trend <0.0001) or the RRS covariables
(HR: 1.53; 95% CI: 1.20 to 1.95; p for trend <0.0001). A
linear increase in CVD risk was observed for women in
the third and fourth quartiles relative to the ﬁrst
quartile, but the second quartile did not clearly ﬁt this
pattern (Table 3). Adding BMI or loop diuretic use to
TABLE 2 Association of NT-proBNP With Incident CVD
Hazard Ratio (95% CI) by Quartile of NT-proBNP
p Value for
Trend
Hazard Ratio
(95% CI) per
1-SD* Unit Increase
in Ln–NT-proBNP p Value
Quartile 1
<50.9 ng/l
Quartile 2
50.9–<82.7 ng/l
Quartile 3
82.7–<140.8 ng/l
Quartile 4
$140.8 ng/l
Age and race/ethnicity adjusted 1.00 0.91 (0.72–1.14) 1.18 (0.95–1.45) 1.55 (1.26–1.92) <0.0001 1.36 (1.26–1.48) <0.0001
MV adjusted† 1.00 0.93 (0.74–1.17) 1.28 (1.03–1.59) 1.62 (1.30–2.02) <0.0001 1.39 (1.28–1.51) <0.0001
MV þ traditional risk factor adjusted‡ 1.00 0.92 (0.71–1.17) 1.29 (1.02–1.63) 1.53 (1.21–1.94) <0.0001 1.37 (1.25–1.49) <0.0001
MV þ RRS adjusted§ 1.00 0.94 (0.73–1.21) 1.29 (1.01–1.64) 1.53 (1.20–1.95) <0.0001 1.36 (1.24–1.49) <0.0001
*The SD of natural logarithm transformed NT-proBNP is 0.838. †Multivariable (MV)-adjusted model is adjusted for age and race/ethnicity, prior diabetes, angina, statin use, and current and
past hormone therapy. ‡MV þ traditional risk factor model is adjusted for the covariables in the MV model, plus current smoking and the natural logs of systolic blood pressure, total and HDL
cholesterol, and blood pressure treatment. §MV þ Reynolds Risk Score (RRS) model: adjusted for the covariables in the MV model, plus current smoking, the natural logs of systolic blood
pressure, total and HDL cholesterol, hsCRP, family history of premature MI, and HbA1c among women with diabetes.
CI ¼ conﬁdence interval; Ln ¼ Ln-transformed; other abbreviations as in Table 1.
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1793the multivariable models presented in Table 2 did
not change the relationship between NT-proBNP and
incident CVD (data not shown).
When CV deaths and coronary and cerebrovascular
events were considered separately, NT-proBNP was
associated with both any CV death and fatal/nonfatal
MI and fatal/nonfatal stroke (Table 3). The risk of CV
death was more than 2.5 times higher for those in the
highest quartile of NT-proBNP relative to those in the
lowest quartile, even after adjusting for the RRS
covariables (HR: 2.66; 95% CI: 1.48 to 4.81; p for
trend <0.0001). Relative to those in the lowest
quartile, these women were also at increased risk of
fatal/nonfatal MI in models adjusted for traditional
risk factor covariables (HR: 1.41; 95% CI: 1.05 to 1.89;
p for trend ¼ 0.004) and RRS covariables (HR: 1.39;
95% CI: 1.02 to 1.88; p for trend ¼ 0.008). The risk ofTABLE 3 Association of NT-proBNP With Cardiovascular Mortality, In
Hazard Ratio (95% CI
Quartile 1
<50.9 ng/l
Quartile 2
50.9–<82.7 ng/l
Cardiovascular mortality
MV adjusted† 1.00 0.84 (0.42–1.68)
MV þ traditional risk factor adjusted‡ 1.00 0.81 (0.40–1.62)
MV þ RRS adjusted§ 1.00 0.82 (0.41–1.66)
MI (fatal and nonfatal)
MV adjusted† 1.00 0.95 (0.70–1.27)
MV þ traditional risk factor adjusted‡ 1.00 0.94 (0.69–1.28)
MV þ RRS adjusted§ 1.00 0.97 (0.70–1.33)
Stroke (fatal and nonfatal)
MV adjusted† 1.00 0.95 (0.72–1.25)
MV þ traditional risk factor adjusted‡ 1.00 0.93 (0.70–1.25)
MV þ RRS adjusted§ 1.00 0.95 (0.71–1.27)
*The SD of natural logarithm transformed NT-proBNP is 0.838. †MV-adjusted model is
therapy. ‡MVþ traditional risk factor model is adjusted for the covariables in the MV mod
blood pressure treatment. §MV þ RRS model is adjusted for the covariables in the MV m
hsCRP, family history of premature MI, and HbA1c among women with diabetes.
Abbreviations as in Tables 1 and 2.fatal/nonfatal stroke was also increased, with an HR
of 1.60 (95% CI: 1.21 to 2.09; p for trend <0.0001) after
adjustment for traditional risk factor covariables
and an HR of 1.60 (95% CI: 1.22 to 2.11; p for
trend <0.0001) after adjusting for RRS covariables.
Further adjustment for BMI did not alter these risk
estimates substantially (data not shown).
Associations between NT-proBNP concentrations
and incident CVD stratiﬁed by a number of sub-
groups are displayed in Online Table 2. In general,
the adjusted association between Ln–NT-proBNP
and incident CVD was consistent across subgroups.
The increase in the risk of incident CVD per 1-SD
unit of Ln–NT-proBNP among past hormone ther-
apy users (HR: 1.71; 95% CI: 1.00 to 2.91; p ¼ 0.049)
appeared to be larger than among current (HR: 1.41;
95% CI: 1.17 to 1.70; p ¼ 0.0003) or never userscident Fatal and Nonfatal MI, and Incident Fatal and Nonfatal Stroke
) by Quartile of NT-proBNP
p Value for
Trend
Hazard Ratio
(95% CI) per
1-SD* Unit Increase
in Ln–NT-proBNP p Value
Quartile 3
82.7–<140.8 ng/l
Quartile 4
$140.8 ng/l
1.79 (0.99–3.24) 2.95 (1.67–5.20) <0.0001 1.95 (1.65–2.31) <0.0001
1.78 (0.98–3.26) 2.82 (1.57–5.05) <0.0001 1.89 (1.59–2.26) <0.0001
1.81 (0.99–3.32) 2.66 (1.48–4.81) <0.0001 1.80 (1.51–2.14) <0.0001
1.25 (0.94–1.65) 1.48 (1.12–1.96) <0.0001 1.33 (1.21–1.47) <0.0001
1.25 (0.93–1.67) 1.41 (1.05–1.89) 0.004 1.28 (1.16–1.42) <0.0001
1.26 (0.93–1.70) 1.39 (1.02–1.88) 0.008 1.26 (1.13–1.40) 0.0002
1.21 (0.93–1.57) 1.72 (1.33–2.22) <0.0001 1.40 (1.28–1.53) <0.0001
1.22 (0.93–1.61) 1.60 (1.21–2.09) <0.0001 1.35 (1.22–1.48) <0.0001
1.21 (0.92–1.60) 1.60 (1.22–2.11) <0.0001 1.34 (1.22–1.48) <0.0001
adjusted for age, race/ethnicity, prior diabetes, angina, statin use, and current and past hormone
el plus current smoking and the natural logs of systolic blood pressure, total and HDL cholesterol, and
odel, plus current smoking, the natural logs of systolic blood pressure, total and HDL cholesterol,
TABLE 4 Changes to
C-statistic
Net reclassiﬁcation imp
Category-less net recla
improvement
Integrated discriminatio
improvement
Values in parentheses are 9
concentrations. The MV an
blood pressure, total and
concentrations. The RRS c
HbA1c among women with
Abbreviations as in Tabl
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1794(HR: 1.28; 95% CI: 1.09 to 1.50; p ¼ 0.003), but these
apparent differences did not reach statistical signif-
icance (p for interaction ¼ 0.03) after correcting for
the number of comparisons (Bonferroni-corrected
p < 0.00278).
When NT-proBNP was added to the multivariable
plus traditional risk factor CVD prediction algorithm,
we observed a small but statistically signiﬁcant
improvement in the c-index, with a difference in c-
statistics of 0.009 (95% CI: 0.009 to 0.010; p ¼
0.0004) and improved classiﬁcation of women into
10-year CVD risk categories of <5%, 5% to <10%, 10%
to <20%, and $20% (NRI 0.059 [95% CI: 0.030 to
0.089]; p < 0.0001) (Table 4). Statistically signiﬁcant
improvements in the category-less NRI and IDI
were also observed (Table 4). When NT-proBNP was
added to an algorithm including the RRS covariates,
we observed a small but statistically signiﬁcant
improvement in the c-index (difference 0.009; 95%
CI: 0.005 to 0.013; p ¼ 0.0001) and improved classi-
ﬁcation of women into the same 10-year CVD risk
categories (NRI 0.033 [95% CI: 0.002 to 0.062];
p ¼ 0.03) (Table 4). Both the category-less NRI and
IDI showed statistically signiﬁcant improvements
after adding NT-proBNP to the RRS covariates
(Table 4). Reclassiﬁcation tables, weighted by cohort
sampling, are displayed in Online Table 3 (for the
multivariable plus traditional risk factor model) and
Online Table 4 (for the RRS). When reweighted to
reﬂect the sampling of the WHI-OS, the addition of
NT-proBNP to the traditional risk factor covariables
would reclassify 7,036 women, 4,246 (60%) correctly,
of a possible 58,216 women. The addition of NT-
proBNP to the RRS would reclassify 6,283 women
(of 58,216), 5,209 (82.9%) correctly.
In sensitivity analyses that added prior diabetes,
angina, statin use, and current and past hormone
therapy to the RRS covariables used in the primary10-Year CVD Risk Prediction Statistics After Adding NT-proBNP to Exist
MV þ Traditional Risk Factor Covariables
MV þ Traditional
Risk Factor
MV þ Traditional Risk
Factor þ NT-proBNP p Valu
0.770 (0.760–0.779) 0.779 (0.769–0.789) 0.00
rovement — 0.059 (0.030–0.089) <0.00
ssiﬁcation — 0.103 (0.020–0.183) 0.02
n — 0.0102 (0.0055–0.016) 0.00
5% CI. *Comparison of the performance of MV þ traditional risk factor covariables þ NT-proB
d traditional risk factor covariables were age, race/ethnicity, prior diabetes, angina, statin us
HDL cholesterol, and blood pressure treatment. †Comparison of the performance of RRS
ovariables were age, race/ethnicity, current smoking, the natural logs of systolic blood p
diabetes.
es 1 and 2.reclassiﬁcation analysis, these results did not differ
substantially (Online Table 5).
DISCUSSION
In this prospective case-cohort study, which included
more than 1,800 cases of incident CVD in women, we
observed a positive association between baseline
NT-proBNP concentrations and the occurrence of a
ﬁrst major CV event, deﬁned as an MI, stroke, or CV
death (Central Illustration). Although a number of
studies have reported this relationship in primary
prevention or general populations, this study is the
ﬁrst to conduct a detailed evaluation of this rela-
tionship in women. This association was evident for
CV mortality, fatal/nonfatal MI, and fatal/nonfatal
stroke, and was consistent across a number of high-
and low-risk subgroups. Finally, we observed that
NT-proBNP concentrations, when added to the cova-
riables included in either the traditional risk factor
or RRS risk prediction algorithms, signiﬁcantly im-
proved our ability to identify women at increased risk
of developing CVD in this multiethnic population
(Central Illustration).
We believe these results are of scientiﬁc and clin-
ical relevance for various reasons. First, the approxi-
mately 1,800 CV events included in this study
represent the largest number of events used to eval-
uate NPs in a primary prevention population,
regardless of the participants’ sex. By comparison, a
2009 meta-analysis of NPs and CVD gathered
approximately 1,000 events in primary prevention
populations (4). Second, although there is consistent
epidemiologic evidence that NP levels associate with
future CV events in general populations, most of the
published studies include few events in women
(11–13), or women were not included in the study
population (6,20). Women are known to have highering Risk Prediction Models
RRS Covariables
e* RRS RRS þ NT-proBNP p Value†
04 0.768 (0.757–0.776) 0.776 (0.765–0.785) 0.0001
01 — 0.033 (0.002–0.062) 0.03
— 0.097 (0.013–0.19) 0.03
01 — 0.0080 (0.0039–0.012) 0.0002
NP concentrations versus MV þ traditional risk factor covariables without NT-proBNP
e, current or past hormone therapy, current smoking, and the natural logs of systolic
covariables þ NT-proBNP concentrations to RRS performance without NT-proBNP
ressure and total and HDL cholesterol, hsCRP, family history of premature MI, and
+ =
CONCLUSION
1    MEASURE NT-proBNP LEVELS IN WOMEN  AND DIVIDE INTO QUARTILES
2    ESTIMATE RELATIVE RISK OF CVD PER QUARTILE OF NT-proBNP
3    ADD NT-proBNP TO EXISTING ALGORTHMS 
NT-proBNP levels may be clinically useful markers of CVD risk in healthy people, 
particularly in those at intermediate risk. However, the thresholds for intervention, 
Adding NT-proBNP to existing algorithms that use established risk factors
Distribution of NT-proBNP levels (percentage of women in study) 
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CENTRAL ILLUSTRATION Improving CVD Risk Prediction in Women by Adding
NT-proBNP Levels to Existing Algorithms
N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentrations were measured in
1,821 women with incident cardiovascular disease (CVD) (746 myocardial infarction, 754
ischemic stroke, 160 hemorrhagic stroke, and 161 cardiovascular death) and a randomly
selected reference subcohort of 1,992 women without CVD at baseline. (1) The distribution
of NT-proBNP concentrations in the reference subcohort. (2) The risk of the combined
cardiovascular endpoint (myocardial infarction, stroke, or cardiovascular death) according
to increasing quartiles of NT-proBNP. (3) The addition of NT-proBNP to traditional risk
factors in risk prediction algorithms, which leads to modest but statistically signiﬁcant
improvements in the ability to predict 10-year cardiovascular disease risk.
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1795baseline concentrations of NPs than men (5,11–13) and
yet have a lower risk of CVD at a given age and risk
factor burden, as well as a lower lifetime risk of CVD
(14,32). Despite these differences, women in our
study who had NT-proBNP concentrations in the
highest quartile ($140.0 ng/l) were at more than 50%
increased risk for the composite CV outcome when
compared with those in the lowest quartile, even af-
ter adjusting for race and other important covariables
included in established risk models.
These results are also consistent with prior work
that has examined the association of NPs and CV
endpoints that exclude HF and/or atrial ﬁbrillation
(4). Indeed, we observed signiﬁcant associations be-
tween NT-proBNP and CV death from any cause, as
well as MI and stroke, an observation that again
is consistent with prior work in other cohorts
(4,11–13,33). The mechanism of the association be-
tween NPs and incident CVD is not known, although
it seems likely that NPs are measuring a component
of CV risk that is either different from or incom-
pletely accounted for by traditional CVD risk
markers. Higher NT-proBNP concentrations may be
evidence of subclinical myocardial ischemia (34,35),
ventricular wall stress, neurohormonal activation,
hypertension, or other conditions. The consistency of
the association with NT-proBNP and incident stroke
raises the possibility that elevated concentrations
may identify individuals with unrecognized and/or
silent atrial ﬁbrillation, who might then be at high
risk of cardioembolic stroke, as was hypothesized in
a recently published study from the ARIC (Athero-
sclerosis Risk in Communities) cohort (33). We also
note that the vast majority of women in the WHI had
NT-proBNP concentrations well below the threshold
that would prompt consideration of HF in patients
with dyspnea (3).
Finally, we observed that adding NT-proBNP to
traditional risk factors and the RRS improves CVD risk
prediction in this multiethnic cohort of women. Only
a handful of studies have tested the ability of NPs to
improve CV risk prediction in primary prevention
cohorts. The results have been mixed, with some
reporting improvements alone or in combination with
other markers (5,6,8,36) and others reporting no
improvement (7). Because women have a lower
prevalence of CVD for a given age distribution, and
because traditional risk factors have superior risk
prediction performance for women than men, even
biomarkers with an independent association with
CVD (such as NT-proBNP) may not improve upon the
performance of existing risk prediction algorithms
(37). Despite these challenges, in our study, NT-
proBNP offered small but statistically signiﬁcant
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Measurement of plasma NP levels can help identify HF
among patients with dyspnea. In healthy men and
women, NP levels correlate with risks of future MI,
stroke, and CV death.
TRANSLATIONAL OUTLOOK: Additional work is
needed to deﬁne the risk prediction thresholds for
blood levels of speciﬁc NPs and to identify preventive
interventions that improve CV outcomes for those
with NP levels above those thresholds.
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1796improvements in the c-statistic, the categorical NRI,
the continuous NRI, and the IDI when added to the
traditional risk factor and RRS covariables. Although
it is difﬁcult to compare improvements in model
performance across populations, we observed im-
provements in the c-statistic for major CV events that
are similar in magnitude to those seen for cardiac
troponin in the ARIC study (38) and close but some-
what smaller than those achieved with a multimarker
score in a European cohort and in the Framingham
Heart Study (8,36). The improvements are smaller
than those seen with coronary calcium scans in the
MESA (Multi-Ethnic Study of Atherosclerosis) (39).
Although statistically signiﬁcant, the improve-
ments in measures of risk prediction we observed
with NT-proBNP were relatively modest. NPs may
merit consideration as useful markers of CVD risk in
those for whom a decision to begin preventive statin
therapy is otherwise unclear, much like other
adjunctive measures of CV risk (40). However, the
therapeutic response to an elevated NP level in an
otherwise healthy individual is not clear. Although
using NPs as a tool to identify those who might
beneﬁt from statins would be one possible clinical
strategy, no trial has tested this approach. Indeed,
elevated NP levels may identify abnormalities in
other biological pathways that are best addressed
with other classes of agents rather than statins. For
example, a recent trial of aggressive renin angio-
tensin and beta-blockade as compared with standard
care in patients with type 2 diabetes and an elevated
NT-proBNP (>125 ng/l) suggested a beneﬁt for
aggressive care (41).
STUDY STRENGTHS AND LIMITATIONS. Strengths of
our study include its prospective nature, inclusion of
a large number of women from a multiethnic cohort,
and a large number of CV events. Limitations include
the fact that the generalizability of our ﬁndings may
be limited to women and the absence of any measures
of renal function in the WHI. Although renal function
is likely to be a confounder of the relationship be-
tween NT-proBNP and incident CVD, we note thatmeasures of renal function are not included as risk
predictors in the Adult Treatment Panel III, the Fra-
mingham CVD risk score, the 2013 American College
of Cardiology/American Heart Association pooled
cohort model, or in the RRS, despite having been
considered for inclusion in the latter (21,22,27,28).
CONCLUSIONS
NT-proBNP showed a positive association with MI,
stroke, and CV death in this large, prospective, case-
cohort study with more than 1,800 ﬁrst CV events.
This association was observed for both fatal and
nonfatal coronary and cerebrovascular events, when
considered separately, and was consistent across
several subgroups. Finally, when we added NT-
proBNP to risk prediction models using traditional
risk factors or the RRS covariables, we saw consistent,
statistically signiﬁcant improvements in the models’
ability to correctly classify women into 10-year cate-
gories of CV risk.
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